HENDERSON, NV / ACCESSWIRE / September 20, 2018 / Small biotech companies have been receiving a ton of interest this year. Just last week, Boehringer Ingelheim's shopping spree continued with a €210m takeover of ViraTherapeutics, an oncolytic virus specialist it has been working with since 2016.
The privately-held German drug maker was impressed with ViraTherapeutics' lead candidate VSV-GP, a cancer therapy that works by infecting tumors with a virus that both destroys malignant cells directly and mobilizes an immune response against them.
German biotech Affimed agreed to an alliance with Roche's Genentech to discover new cancer immunotherapies with an amazing $5 billion-dollar deal.
We've been looking for the next biotech opportunities on the market and think we found it. Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, has recently announced an amendment to its Registration trial in ocular melanoma liver metastases, a disease that has shown resistance to the new immunotherapies. The company believes the amendment to the trial will allow it to complete enrollment by the middle of 2019.
Delcath Systems, Inc. (DCTH)
Market Cap: $3.03M Share Price: $3.25
DCTH an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its shareholders of the expiration on Wednesday September 26, 2018. The subscription rights will be exercisable until 5:00 p.m. Eastern time on September 26, 2018, though most broker dealers will require holders of rights to exercise in advance of this date. Holders of rights should confirm deadlines with their brokers to subscribe in a timely manner.
Under the terms of the rights offering, Delcath distributed, at no charge, non-transferable subscription rights to purchase 500 shares of its common stock to holders of record for each share of common stock held on the record date, and to holders of its warrants to purchase common stock. Each basic subscription right entitles the right holder of record to purchase 500 shares of common stock at the subscription price of $1.75 per share. Holders of rights who exercise their basic subscription rights in full will also have an over-subscription privilege, pursuant to which they may subscribe to purchase additional shares at the subscription price to the extent that not all basic subscription rights are exercised, subject to certain limitations and as more fully described in a prospectus relating to the rights offering.
CEL-SCI Corporation (NYSE American: CVM)
Market Cap: $105.57M, Share Price: $3.86
CEL-SCI Corporation (NYSE American: CVM) announced they have received $5,435,367 through the exercise of warrants to purchase shares of the Company's common stock during August through September 13, 2018. As of September 13, 2018, CEL-SCI had 27,351,324 outstanding shares of common stock.
Roche Holdings, AG. (RHHBY)
Market Cap: $207B Share Price: $30.68
Mentioned above Roche is the parent company of the $5 billion dollar deal. The company is currently going through an issue in the UK with the pricing of their MS drug.
Affirmed N.V. (AFMD)
Market Cap: $265.15M Share Price: $4.25
Affirmed is the company Roche made the deal with, the stock has pulled back a bit since it's large jump on the news. It will be interesting to watch from here.
Marinus Pharmaceuticals, Inc. (MRNS)
Market Cap: $283.67M Share Price: $7.00
Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, CEO, Christopher M. Cashman, recently presented a company overview at the Baird 2018 Healthcare Conference.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and seven thousand dollars total by Regal Consulting. LLC, for news commentary articles for DCTH. DCTH and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communications, LLC. and the hiring party Regal Consulting, LLC. may buy or sell additional shares of DCTH in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
For Full Legal Disclaimer Click Here.
Regal Consulting, LLC.For Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: ACR Communications LLC